Delayed Cutaneous Adverse Reaction of the AstraZeneca COVID-19 Vaccine in a Breastfed Female Infant: A Coincidence or a Rare Effect?

The ChAdOx1 nCoV-19 vector vaccine (Vaxzevria, AstraZeneca, Cambridge, UK) was developed at Oxford University and is considered safe for the administration in lactating mothers. Nevertheless, as a novel vaccine, there are gaps in the knowledge regarding possible adverse events in breastfeeding infan...

Descripción completa

Detalles Bibliográficos
Autores principales: Diogo, Patrícia, Correia, Gil, Martins, João B., Soares, Rui, Palma, Paulo J., Santos, João Miguel, Gonçalves, Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031970/
https://www.ncbi.nlm.nih.gov/pubmed/35455352
http://dx.doi.org/10.3390/vaccines10040602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031970/
https://www.ncbi.nlm.nih.gov/pubmed/35455352
http://dx.doi.org/10.3390/vaccines10040602

Ejemplares similares